AbbVie (ABBV) Stock Forecast & Price Target

$171.57 -5.23 (-2.96%)

As of 04/16/2025 03:58 PM Eastern

AbbVie - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
7

Buy
19

Based on 26 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 7 have given a hold rating, 16 have given a buy rating, and 3 have given a strong buy rating for ABBV.

Consensus Price Target

$210.71
22.82% Upside

According to the 26 analysts' twelve-month price targets for AbbVie, the average price target is $210.71. The highest price target for ABBV is $241.00, while the lowest price target for ABBV is $180.00. The average price target represents a forecasted upside of 22.82% from the current price of $171.57.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

ABBV Analyst Ratings Over Time

Type	Current Forecast 4/17/24 to 4/17/25	1 Month Ago 3/18/24 to 3/18/25	3 Months Ago 1/18/24 to 1/17/25	1 Year Ago 4/18/23 to 4/17/24
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	17 Buy rating(s)	17 Buy rating(s)	10 Buy rating(s)
Hold	7 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$210.71	$211.45	$205.50	$177.43
Forecasted Upside	22.82% Upside	-1.10% Downside	19.83% Upside	8.03% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	22.82% Upside	23,520.13% Upside	27.72% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/11/2025	Morgan Stanley 3 of 5 stars		Reiterated Rating	Hold ➝ Hold
4/8/2025	The Goldman Sachs Group 3 of 5 stars	Asad Haider Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Neutral	$194.00	+5.94%
3/17/2025	Erste Group Bank 3 of 5 stars	H. Engel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$210.00 ➝ $240.00	+15.11%
3/4/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$200.00 ➝ $223.00	+4.67%
2/3/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$205.00 ➝ $215.00	+13.03%
2/3/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$211.00 ➝ $217.00	+14.50%
2/3/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Navin Jacob Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$181.00 ➝ $190.00	+0.71%
2/3/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$218.00 ➝ $220.00	+19.63%
2/3/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$212.00 ➝ $214.00	+16.37%
Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.
2/3/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$208.00 ➝ $215.00	+16.91%
12/17/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$220.00	+25.13%
12/5/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
12/5/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$180.00	+1.95%
11/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/22/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$206.00	+19.64%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$205.00	+20.85%
11/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$210.00 ➝ $200.00	+16.74%
11/4/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$203.00	+6.58%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $212.00	+9.75%
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$195.00 ➝ $225.00	+16.22%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00	+8.40%
6/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$185.00	+14.08%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$150.00	+5.60%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$170.00 ➝ $160.00	+18.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:21 AM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 8, 2025. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie has received multiple upgrades from analysts, including a "strong-buy" rating, indicating strong confidence in the company's future performance.
The stock has a consensus price target of $211.45, suggesting potential for price appreciation from its current trading price of $186.11.
Institutional investors own 70.23% of AbbVie, reflecting strong institutional confidence and support for the company's growth prospects.
Recent insider selling, while notable, can sometimes indicate a strategic reallocation rather than a lack of confidence in the company's future, as insiders still hold a small percentage of shares.
AbbVie has a solid market capitalization of $329.22 billion, which provides stability and resources for continued research and development in pharmaceuticals.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

Insiders have sold a significant number of shares recently, totaling 113,471 shares worth over $23 million, which may raise concerns about their confidence in the company's future performance.
The company's high P/E ratio of 77.55 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
AbbVie has a relatively low current ratio of 0.66, indicating potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
The stock has experienced volatility, with a one-year low of $153.58 and a high of $218.66, which may indicate uncertainty in its price stability.
With a debt-to-equity ratio of 17.94, AbbVie carries a significant amount of debt, which could pose risks if the company faces financial challenges or market downturns.

ABBV Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $210.71, with a high forecast of $241.00 and a low forecast of $180.00.
: 26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 7 hold ratings, 16 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.
: According to analysts, AbbVie's stock has a predicted upside of 22.82% based on their 12-month stock forecasts.
: Over the previous 90 days, AbbVie's stock had 1 upgrade by analysts.
: AbbVie has been rated by research analysts at Bank of America, BMO Capital Markets, Citigroup, Erste Group Bank, Guggenheim, Morgan Stanley, Raymond James, The Goldman Sachs Group, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.85 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ABBV) was last updated on 4/17/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Stock Forecast & Price Target